IN SILICO STUDY OF NATURAL PYRIDOACRIDINE AGAINST CDK- 2 AND CDK-6 CANCERAwik Puji Dyah Nurhayati, Fitri Lianingsih, Adik Mayang Indiani and Shabrina Syifa Ghaissani
Cancer is a major public health problem and leading cause of deaths worldwide. The number of cancer cases in the world per year is predicted to reach up to 23.6 million by 2030. Cancer is the over-proliferation of the cells that can be controlled by the cell cycle. The cyclin-dependent kinases (Cdks) are protein that is activated during cell cycle transitions. Cdk-2 is responsible as a target of a checkpoint in the S phase cell cycle. Cdk-6 as a transcriptional regulator to support homeostatic in the cell cycle. Cdk-2 and Cdk-6 are now used as the candidate for cancer treatment. Thus, this study is aimed to determine the potential of Pyridoacridine containing natural anticancer pigments (PCNPs) using the molecular docking approach. In this work, molecular docking using Glide is performed to know glide Gscore and Glide energy. Thus, this study explains the pathway Cdk-2 and Cdk-6 as a therapeutic target in apoptosis. The result of the study was meridine compound of PCNPs has the best score in Cdk-2 and Cdk-6. So, PCNPs may inhibit Cdk-2 and Cdk-6 in cancer. PCNPs is one of the anticancer potential candidates to develop. The amino acid residues like leucine and valine can be an important amino acid that can bind and interact with protein kinase cdk- 2 and cdk-6. The mechanism action of PCNPs as an inhibitor protein kinase in cancer.